Dr. Jag Shur, Vice President, Science & Technology at Nanopharm, and Dr. Will Ganley, Head of Computational Pharmaceutics, recently discussed SmartTrack™ and Nanopharm’s extended capabilities in support of alternative bioequivalence at a workshop which was held jointly between the FDA and the Center for Research on Complex Generics (CRCG) at the University of Maryland, Baltimore and the University of Michigan.
Jag Shur’s presentation focused on realistic in vitro tools. Our partner Jan De Backer from FLUIDDA spoke on their in silico CFD models for studying regional deposition in patient-specific models.
Will Ganley, whose presentation on how in silico patient-specific PBPK models form part of a platform as an alternative to CCEP BE studies for inhaled generics, said this about the event itself: “The event was unique in that of the 85 in-person attendees a large proportion of them were from the FDA. This allowed us to have conversations and ask questions during the sessions and over lunch or coffee, which I had never experienced before. The workshop opened with a statement that only 4/33 of currently approved inhaled medicines in the US have approved generics which was motivating.”
Will said, “The talks covered a wide range of topics from the shortcomings of current bioequivalence approaches to novel or alternative in silico, in vitro and in vivo studies that could help us better demonstrate bioequivalence for orally inhaled products. There was a lot of healthy discussion, especially during the small group discussions and panel sessions. There were a lot of differences of opinion on the best way to bring the industry’s expertise together to solve this problem, but it was clear that the basic research is mainly done. We have already established the tools we need to make this happen. The final challenge is figuring out how to bring them all together for each of the remaining products that don’t have approved generics.”
“Overall, the event was excellent. We covered a lot of ground, and the attendees were keen to share experience and opinions. My perspective has shifted on a few things. Still, I am confident that Nanopharm’s approach of bringing relevant in vitro studies and in silico methods together ticks all the boxes.”
More information about the event can still be found here.
Related Posts
FDA’s Evolving Stance on In-Silico Studies in Bioequivalence Testing
The paper titled “Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques” explores the use of advanced analytical methods to improve our understanding of the performance of dry powder inhalers (DPIs).
Nanopharm Newsletter November 2024
Nanopharm is leading innovation in OINDP, inhalation, and nasal drug delivery with FDA collaboration and advanced spray-drying technology.
Interview with Jane Provis Evans, Head cGMP services at Nanopharm
In the ever-evolving world of pharmaceuticals, the importance of stringent quality control cannot be overstated. This interview with Jane Provis-Evans, Head of cGMP Analysis at Nanopharm, sheds light on the critical role of cGMP testing in the development and optimization of drug-device combinations, particularly for orally inhaled and nasal drug products (OINDPs). With the launch of Nanopharm’s new GMP services, the company is well-positioned to help clients bring innovative treatments to patients.
